Noble Financial Has Negative Opinion of COCP FY2026 Earnings

Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) – Equities researchers at Noble Financial cut their FY2026 earnings estimates for Cocrystal Pharma in a report released on Tuesday, November 17th. Noble Financial analyst R. Leboyer now expects that the company will post earnings per share of ($0.83) for the year, down from their previous forecast of ($0.61). The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.69) per share. Noble Financial also issued estimates for Cocrystal Pharma’s Q4 2026 earnings at ($0.21) EPS and FY2027 earnings at ($0.70) EPS.

COCP has been the subject of a number of other research reports. Weiss Ratings cut Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. HC Wainwright reaffirmed a “buy” rating on shares of Cocrystal Pharma in a research report on Friday, October 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Check Out Our Latest Stock Analysis on COCP

Cocrystal Pharma Trading Down 3.3%

Shares of COCP opened at $0.98 on Thursday. Cocrystal Pharma has a 12 month low of $0.76 and a 12 month high of $2.03. The stock has a fifty day moving average price of $1.07 and a 200-day moving average price of $1.10. The firm has a market cap of $18.82 million, a PE ratio of -1.27 and a beta of 1.60.

Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.10 million.

About Cocrystal Pharma

(Get Free Report)

Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.

See Also

Earnings History and Estimates for Cocrystal Pharma (NASDAQ:COCP)

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.